Table 3 Details of cutaneous and acral melanoma by UVR and non-UVR signature

From: Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas

	Cutaneous melanoma			Acral melanoma
	UVR signature N (%)	Non-UVR signature N (%)	Difference in means (95% CI)	UVR signature N (%)	Non-UVR signature N (%)	Difference in means (95% CI)
Cases	136	4		3	32
Gender
Male	86	2		3	11
Female	49	2		0	21
Age at time of primary (years)
Mean (s.d.)	57.3 (18.6)	59.1 (7.9)	1.8 (−10.1, 13.6)	60.9 (3.2)	70.5 (13.6)	9.6 (3.0, 16.2)
Q1, Median, Q3	46, 59.0, 71	56, 59.8, 63		59, 61.2, 62	63, 71.8, 80
Breslow thickness (mm)
Mean (s.d.)	4.1 (4.0)	9.5 (8.0)	5.3 (−7.3, 18.0)	2.8 (1.4)	4.9 (3.2)	2.1 (−0.5, 4.7)
Q1, Median, Q3	1.4, 2.7, 5.2	6.5, 8.6, 11.6		2.2, 3.2 3.6	2.6, 4.3, 6.3
Mitoses (/mm²)
Mean (s.d.)	7.9 (8.1)	14.0 (11.9)	6.1 (−12.6, 24.7)	2.7 (0.6)	4.5 (3.6)	1.8 (0.4, 3.3)
Q1, Median, Q3	3, 6.0, 10	5, 10.5, 19.5		2.5, 3, 3	2, 4.0, 6.5
Ulceration present	42 (31)	3 (75)		2 (67)	14 (44)
Cases at least stage III at diagnosis	41 (30)	3 (75)		3 (100)	13 (41)
WHO melanoma subtype
NM	59 (43)	1(25)		0 (0)	3 (9)
SSM	48 (35)	3 (75)		0 (0)	0 (0)
DM	9 (7)	0 (0)		0 (0)	2 (6)
AL	0 (0)	0 (0)		3 (100)	30 (85)
LM	3 (2)	0 (0)		0 (0)	0 (0)
Not classified/unknown primary	17 (13)	0 (0)		0 (0)	0 (0)
Vascular invasion present	8 (6)	2 (50)		1 (33)	5 (16)
Lymphatic invasion present	8 (6)	2(50)		0 (0)	6 (19)
Neurotropism present	3 (2)	0 (0)		0 (0)	4 (13)
Satellites present	5 (4)	0 (0)		0 (0)	3 (9)
Primary tumor H&E slides reviewed	44 (32)	4 (100)		3 (100)	23 (72)
TIL distribution
Negative	9 (20)	3 (75)		0 (0)	6 (26)
Focal	25 (57)	1 (25)		3 (100)	10 (43)
Multifocal	8 (18)	0 (0)		0 (0)	7 (30)
Diffuse	2 (5)	0 (0)		0 (0)	0 (0)
TIL density
Negative	9 (20)	3 (75)		0 (0)	6(26)
Mild	27 (61)	1 (25)		3 (100)	13 (57)
Moderate	8 (18)	0 (0)		0 (0)	4 (17)
Marked	0 (0)	0 (0)		0 (0)	0 (0)
Pigment distribution
0%	23(52)	2 (50)		1 (33)	11 (48)
0–25%	14 (32)	1 (25)		2 (67)	9 (39)
25–50%	5 (11)	1 (25)		0 (0)	2 (9)
>50%	2 (5)	0 (0)		0 (0)	1 (4)
Pigment density
Negative	23 (52)	2 (50)		1 (33)	11 (48)
Mild	8 (18)	0 (0)		0 (0)	4 (17)
Moderate	7 (16)	2 (50)		2 (67)	7 (30)
Marked	6 (14)	0 (0)		0 (0)	1 (4)
Regression in melanoma
0%	34 (77)	4 (100)		1(33)	11 (48)
0–25%	7 (16)	0 (0)		2 (67)	10 (43)
25–50%	3 (7)	0 (0)		0 (0)	1 (4)
>50%	0 (0)	0 (0)		0 (0)	1 (4)
Cell size
< × 2 lymphocyte	0 (0)	0 (0)		0 (0)	1 (4)
= × 2 lymphocyte	2 (5)	0 (0)		0 (0)	1 (4)
> × 2 lymphocyte	42 (95)	4 (100)		3 (100)	21 (91)
Cell shape
Epithelioid	25 (57)	3 (75)		1 (33)	10 (43)
Mixed	13 (30)	1 (25)		2 (67)	9 (39)
Spindled	6 (14)	0 (0)		0 (0)	4 (17)
Tumor border
Pushing	30 (68)	4 (100)		1 (33)	14 (61)
Infiltrative	13 (30)	0 (0)		2 (67)	8 (35)
Unable to assess	1 (2)	0 (0)		0 (0)	1 (4)
Solar elastosis
Absent	7 (16)	4 (100)		3 (100)	23 (100)
Mild	13 (30)	0 (0)		0 (0)	0 (0)
Moderate	15 (34)	0 (0)		0 (0)	0 (0)
Severe	8 (18)	0 (0)		0 (0)	0 (0)
Unable to assess	1 (2)	0 (0)		0 (0)	0 (0)
Lateral circumscription
Discontinuous	0 (0)	0 (0)		0 (0)	0 (0)
Gradual	16 (36)	1 (25)		3 (100)	11 (48)
Abrupt	19 (43)	2 (50		0 (0)	9 (39)
Unable to assess	9 (20)	1 (25)		0 (0)	3 (13)
Upward spread
Absent	13 (30)	0 (0)		1 (33)	15 (65)
Occasional	20 (45)	3 (75)		1 (33)	2 (9)
Moderate	2 (5)	0 (0)		1 (33)	4 (17)
Marked	0 (0)	0 (0)		0 (0)	1 (4)
Unable to assess	9 (20)	1 (25)		0 (0)	1 (4)

Abbreviations: AL, acral lentiginous; SSM, superficial spreading melanoma; NM, nodular melanoma; DM, desmoplastic melanoma; LM, lentigo maligna; TILS, tumor-infiltrating lymphocytes.
Values are expressed as n (%) unless otherwise noted. Total percentages that do not add up to 100% have missing values.

Back to article page

Table 3 Details of cutaneous and acral melanoma by UVR and non-UVR signature

Search

Quick links